The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...

Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy ...

The ITC found that "multiple bad actors" have been importing or selling knockoff copies of Lilly's tirzepatide.

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

Eli Lilly’s request to intervene in a suit filed by compounding pharmacies against the FDA reflects a belief the outcome could affect its business and that the FDA does not adequately represent its ...

Eli Lilly (NYSE:LLY) has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

Glaswegian cosmetic practitioner Awfa Paulina said weight-loss drugs can be 'effective tools', but that no guarantees can be ...

As many people begin their New Year resolutions to live happier lives, some are turning to the help of weight loss ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

According to a recent release from GlobalData, Eli Lilly’s obesity offering could become a potential leader in the market.

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies to produce Victoza, also known as liraglutide, following a proposal by the ...

Can Ozempic and similar drugs cause muscle and bone loss? Discover how to maintain your health while achieving weight loss ...